Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide suppositories versus placebo for acute radiation proctitis in men with prostate cancer receiving external beam radiotherapy
2024-519359-27-00Phase 2Authorised
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Apr 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in Acute radiation proctitis (ARP) comparing Budenofalk suppository arm with Placebo suppository arm (2 arms). Primary endpoint: Time to first improvement in CTCAE proctitis grading. Planned start Apr 2026; status: authorised.
02
Drugs
budesonide
03
Conditions
Acute radiation proctitis (ARP)
Beyond the preview
Go deeper on 2024-519359-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519359-27-00.